---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-022333"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:48:19.674526+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA expands Pfizer collaboration to support Phase 2/3 registrational trial for darovasertib + crizotinib in 1L MUM

## Summary
- Amendment increases crizotinib supply for planned Phase 2/3 trial evaluating darovasertib + crizotinib in first-line HLA-A2 negative MUM.
- Pfizer to provide first defined quantity at no cost; additional second quantity at lump-sum cost to IDEAYA.
- Termination of prior Pfizer agreement for Phase 1 trial in cMET-driven tumors (NSCLC/HCC).
- Trial initiation targeted for Q2 2023; PFS primary endpoint for potential accelerated approval.
- IDEAYA owns commercial rights to darovasertib subject to Novartis license obligations.

## SEC filing metadata
- accession: 0000950170-23-022333
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017023022333/0000950170-23-022333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017023022333/idya-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-022333
- JSON: https://secwatch.observer/filing/0000950170-23-022333.json
- Plain text: https://secwatch.observer/filing/0000950170-23-022333.txt

## Key facts
- Material Agreements
  IDEAYA Biosciences, Inc. terminated Clinical Trial Collaboration and Supply Agreement with Pfizer Inc. valued at terminates the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Third Pfi (effective 2023-05-12).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Pfizer Inc.
  - Value: terminates the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Third Pfi
  - Effective: 2023-05-12
  source text: Amendment No. 1 additionally terminates the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Third Pfizer Agreement”) between the Company and Pfizer relating to Pfizer’s supply of crizotinib in support of the Company’s potential Phase 1 clinical trial to evaluate darovasertib in combination with crizotinib in cMET driven tumors such as non-small cell lung cancer and/or hepatocellular carcinoma.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017023022333/0000950170-23-022333-index.htm
- Material Agreements
  IDEAYA Biosciences, Inc. amended Clinical Trial Collaboration and Supply Agreement with Pfizer Inc. valued at increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi (effective 2023-05-12).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Pfizer Inc.
  - Value: increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi
  - Effective: 2023-05-12
  source text: On May 16, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced that on May 12, 2023 it had entered into an Amendment No. 4 (“Amendment No. 4”) to the Clinical Trial Collaboration and Supply Agreement dated March 11, 2020 (the “Pfizer Agreement”) between the Company and Pfizer Inc. (“Pfizer”) relating to Pfizer’s supply of its investigational cMET inhibitor, crizotinib, in support of the Company’s ongoing Phase 1/2 clinical trial evaluating the Company’s investigational small molecule protein kinase C, or PKC, inhibitor darovasertib in combination with crizotinib in metastatic uveal melanoma, or MUM, patients.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017023022333/0000950170-23-022333-index.htm
- Material Agreements
  IDEAYA Biosciences, Inc. amended Clinical Trial Collaboration and Supply Agreement with Pfizer Inc. valued at increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi (effective 2023-05-12).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Pfizer Inc.
  - Value: increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi
  - Effective: 2023-05-12
  source text: Additionally, on May 16, 2023, the Company announced that on May 12, 2023 it had entered into an Amendment No. 1 (“Amendment No. 1”) to the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Second Pfizer Agreement”) between the Company and Pfizer relating to Pfizer’s supply of crizotinib in support of the Company’s planned potential registration-enabling Phase 2/3 clinical trial evaluating darovasertib in combination with crizotinib in HLA-A2(-) MUM patients.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017023022333/0000950170-23-022333-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.